Levels of eosinophils and interleukin-5 and severity of atopic dermatitis in the presence of psychosocial stress

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Skin damage in atopic dermatitis is caused by the participation of several immune cells and their inflammatory mediators. However, data on correlations between the severity of atopic dermatitis, combined with and without food allergies (severity of atopic dermatitis (SCORAD) index, etc.), and the levels of eosinophils and interleukin-5 are scarce and contradictory. No studies have compared the frequency of eczematous reactions occurring at different times or immediate allergic reactions in the above patients. Moreover, no studies or certain studies have reported results on the frequency of the combination of atopic dermatitis and food allergies, its various degrees of severity depending on these indicators, levels and relationships of the concentration of eosinophils, and interleukin-5 in the presence of psychosocial stress.

AIM: To study the frequency and severity of the course, skin reactions in patients with atopic dermatitis, with and without food allergies, and levels and correlations of interleukin-5 and eosinophils in the presence of psychosocial stress in patients in the Donbass region.

MATERIALS AND METHODS: A total of 165 patients with atopic dermatitis were examined. Questionnaire survey, anamnesis collection, and general clinical and specific allergological examinations were performed, and the levels of interleukin-5, absolute quantity, and percentage of eosinophils in the peripheral blood were determined. Two subgroups of patients with atopic dermatitis were analyzed: 1) those with food allergies and 2) those without food allergies. Persons living in areas with high and low shelling intensities were also identified. Data were statistically processed using the domestic program Medstat (Donetsk).

RESULTS: In patients with atopic dermatitis, randomly selected from those who applied for an appointment with allergists-immunologists, this disease was combined with food allergy in 81.2% of cases. The severity of atopic dermatitis and eosinophil levels were significantly higher in the group with food allergies. Stable direct reliable correlations of varying strength have been established between the severity of atopic dermatitis (SCORAD index and its indicators) and the absolute quantity, percentage of eosinophils, and interleukin-5 level, as well as between the above laboratory parameters. Differences were found in the frequency of recording eczematous and immediate skin reactions. The residence of patients with atopic dermatitis with and without food allergies in areas that differed in shelling intensity was associated with the severity of atopic dermatitis and the level of eosinophils and interleukin-5.

CONCLUSION: In most patients, atopic dermatitis is combined with food allergy, and the severity of its combination with food allergy increases. Therefore, reliable correlations of the SCORAD index with blood eosinophilia and interleukin-5 levels are revealed. The severity of atopic dermatitis and biomarkers in both subgroups increased when they lived in areas with high intensity of shelling.

Full Text

Restricted Access

About the authors

Aleksandr S. Prilutskiy

M. Gorky Donetsk National Medical University

Email: aspr@mail.ru
ORCID iD: 0000-0003-1409-504X
SPIN-code: 3914-7807

MD, Dr. Sci. (Med.), Professor

Russian Federation, Donetsk, Donetsk People's Republic

Yuliya A. Lygina

M. Gorky Donetsk National Medical University

Author for correspondence.
Email: alikora21@mail.ru
ORCID iD: 0000-0002-2909-0682
SPIN-code: 6957-5817

MD

Russian Federation, Donetsk, Donetsk People's Republic

References

  1. Atopic dermatitis: Clinical recommendations (Approved by the Ministry of Health of the Russian Federation). Moscow: Russian Society of Dermatovenerologists and Cosmetologists, Russian Association of Allergologists and Clinical Immunologists, The Union of Pediatricians of Russia; 2021. (In Russ).
  2. Tsakok T, Marrs T, Mohsin M, et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071–1078. doi: 10.1016/j.jaci.2015.10.049
  3. Papapostolou N, Xepapadaki P, Gregoriou S, Makris M. Atopic dermatitis and food allergy: A complex interplay what we know and what we would like to learn. J Clin Mede. 2022;11(14):4232. doi: 10.3390/jcm11144232
  4. Wu ZH, Zhong J, Su CL, et al. Eosinophilia triggers changes in IL-5, eotaxin and IL-17, and acts as a prognostic biomarker for atopic dermatitis. Tropical J Pharmaceutical Res. 2017;16(5):1167–1172. doi: 10.4314/tjpr.v16i5.26
  5. Kimura M, Obi M, Saito M. Japanese cedar-pollen-specific IL-5 production in infants with atopic dermatitis. Int Arch Allergy Immunol. 2004;135(4):343–347. doi: 10.1159/000082330
  6. Kimura M, Obi M. Ovalbumin-induced IL-4, IL-5 and IFN-gamma production in infants with atopic dermatitis. Int Arch Allergy Immunol. 2005;137(2):134–140. doi: 10.1159/000085792
  7. Gürkan A, Yücel AA, Sönmez C, et al. Serum cytokine profiles in infants with atopic dermatitis. Acta Dermatovenerol Croat. 2016;24(4):268–273.
  8. Mizawa M, Yamaguchi M, Ueda C, et al. Stress evaluation in adult patients with atopic dermatitis using salivary cortisol. Biomed Res Int. 2013. doi: 10.1155/2013/138027
  9. Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis: A review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174–1190.e1. doi: 10.1016/j.jaci.2021.01.013
  10. Hu Y, Liu S, Liu P, et al. Clinical relevance of eosinophils, basophils, serum total IgE level, allergen-specific IgE, and clinical features in atopic dermatitis. J Clin Lab Anal. 2020;34(6):e23214. doi: 10.1002/jcla.23214
  11. Jenerowicz D, Czarnecka-Operacz M, Silny W. Peripheral blood eosinophilia in atopic dermatitis. Acta Dermatovenerol Alp Pannonica Adriat. 2007;16(2):47–52.
  12. Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics. 1998;101(3):E8. doi: 10.1542/peds.101.3.e8
  13. Calvani MA, Anania C, Caffarelli C, et al. Food allergy: An updated review on pathogenesis, diagnosis, prevention and management. Acta Biomed. 2020;91(Suppl 11):1–17. doi: 10.23750/abm.v91i11-S.10316
  14. Kishkun AA. Clinical laboratory diagnostics: Textbook. 2nd revised and updated. Moscow: GEOTAR-Media; 2019. 1000 p. (In Russ).
  15. Prilutsky AS. Development and use of innovative methods of immune pathology diagnosis and treatment. Arch Clin Exp Med. 2016;25(2):127–132.
  16. Koike Y, Takahashi N, Yada Y, et al. Selectively high level of serum interleukin 5 in a newborn infant with cow's milk allergy. Pediatrics. 2011;127(1):e231–234. doi: 10.1542/peds.2009-2318
  17. Biancotto A, Wank A, Perl S, et al. Correction: Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects. PLoS One. 2015;10(7):e0132870. doi: 10.1371/journal.pone.0132870
  18. Bonett DG, Wright TA. Sample size requirements for estimating pearson, kendall and spearman correlations. Psychometrika. 2000;65(1):23–28. doi: 10.1007/BF02294183
  19. Lyakh YE, Guryanov VG, Khomenko VN, Panchenko OA. Fundamentals of computer biostatistics: Analysis of information in biology, medicine and pharmacy with the statistical package MedStat. Donetsk: Papakitsa E.K.; 2006. 214 p. (In Russ).
  20. Tokura Y, Hayano S. Subtypes of atopic dermatitis: From phenotype to endotype. Allergol Int. 2022;71(1):14–24. doi: 10.1016/j.alit.2021.07.003
  21. Celakovska J, Bukač J. Food hypersensitivity reactions and peripheral blood eosinophilia in patiens suffering from atopic dermatitis. Food Agric Imunol. 2017;28:35–43. doi: 10.1080/09540105.2016.1202209
  22. Kondo S, Yazawa H, Jimbow K. Reduction of serum interleukin-5 levels reflect clinical improvement in patients with atopic dermatitis. J Dermatol. 2001;28(5):237–243. doi: 10.1111/j.1346-8138.2001.tb00124.x
  23. Antúnez C, Torres MJ, Mayorga C, et al. Different cytokine production and activation marker profiles in circulating cutaneous-lymphocyte-associated antigen T cells from patients with acute or chronic atopic dermatitis. Clin Exp Allergy. 2004;34(4):559–566. doi: 10.1111/j.1365-2222.2004.1933.x
  24. А Raap U, Werfel T, Jaeger B, Schmid-Ott G. [Atopic dermatitis and psychological stress. (In German)]. Hautarzt. 2003;54(10):925–929. doi: 10.1007/s00105-003-0609-z
  25. Akan A, Azkur D, Civelek E, et al. Risk factors of severe atopic dermatitis in childhood: Single-center experience. Turk J Pediatr. 2014;56(2):121–126.
  26. Holm JG, Hurault G, Agner T, et al. Immunoinflammatory biomarkers in serum are associated with disease severity in atopic dermatitis. Dermatology. 2021;237(4):513–520. doi: 10.1159/000514503
  27. Bacharier LB, Jackson DJ. Biologics in the treatment of asthma in children and adolescents. J Allergy Clin Immunol. 2023;151(3):581–589. doi: 10.1016/j.jaci.2023.01.002
  28. Global Initiative for Asthma [Internet]. Global Strategy for Asthma Management and Prevention. GINA; Fontana, WI, USA; 2002. Available from: https://ginasthma.org/. Accessed: 06.07.2023.
  29. Butala S, Castelo-Soccio L, Seshadri R, et al. Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: Clinical considerations. J Allergy Clin Immunol Pract. 2023;11(5):1361–1373. doi: 10.1016/j.jaip.2023.03.011
  30. Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: Results from a phase 3, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023:189(1):23–32. doi: 10.1093/bjd/ljad096
  31. Makowska K, Nowaczyk J, Blicharz L, et al. Immunopathogenesis of atopic dermatitis: Focus on interleukins as disease drivers and therapeutic targets for novel treatments. Int J Mol Sci. 2023;24(1):781. doi: 10.3390/ijms24010781
  32. National Institutes of Health Cg. A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3). Active study: Eli Lilly and Company. 2018, March. Study identifier: NCT03334435. Available from: https://clinicaltrials.gov/study/NCT03334435. Accessed: 06.07.2023.
  33. Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60(5):693–696. doi: 10.1111/j.1398-9995.2005.00791.x

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright © Pharmarus Print Media, 2023



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies